Search research articles
Contact Us
Filters
Showing results (231-240 of 273) with videos related to
Page
of 28
Sort By:
Clinical Genitourinary Cancer
|
November 14, 2020
Management of Muscle-Invasive Bladder Cancer During a Pandemic: Impact of Treatment Delay on Survival Outcomes for Patients Treated With Definitive Concurrent Chemoradiotherapy
Benjamin W Fischer-Valuck, Jeff M Michalski, Joanna G Harton, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 25, 2025
Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115)
Daniel A Hamstra, James J Dignam, Deborah W Bruner, et al.
European Urology Oncology
|
March 25, 2020
Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences
Joep J de Jong, Joost L Boormans, Bas W G van Rhijn, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 4, 2021
Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial
Christopher U Jones, Stephanie L Pugh, Howard M Sandler, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 3, 2023
Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials
Paul L Nguyen, Huei-Chung Rebecca Huang, Daniel E Spratt, et al.
European Urology Oncology
|
July 17, 2025
Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 Trial
Ryan M Phillips, James A Proudfoot, Elai Davicioni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 4, 2023
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group
Ashish M Kamat, Andrea B Apolo, Marek Babjuk, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 19, 2018
Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer
Himanshu R Lukka, Stephanie L Pugh, Deborah W Bruner, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 3, 2023
Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial
Daniel E Spratt, Vinnie Y T Liu, Jeff Michalski, et al.
European Urology
|
June 26, 2025
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data
Sarah Burdett, David J Fisher, Jayne F Tierney, et al.
Page
of 28
Search research articles
Search
Showing results (231-240 of 273) with videos related to
Sort By:
Page
of 28
Clinical Genitourinary Cancer
|
November 14, 2020
Management of Muscle-Invasive Bladder Cancer During a Pandemic: Impact of Treatment Delay on Survival Outcomes for Patients Treated With Definitive Concurrent Chemoradiotherapy
Benjamin W Fischer-Valuck, Jeff M Michalski, Joanna G Harton, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 25, 2025
Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115)
Daniel A Hamstra, James J Dignam, Deborah W Bruner, et al.
European Urology Oncology
|
March 25, 2020
Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences
Joep J de Jong, Joost L Boormans, Bas W G van Rhijn, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 4, 2021
Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial
Christopher U Jones, Stephanie L Pugh, Howard M Sandler, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 3, 2023
Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials
Paul L Nguyen, Huei-Chung Rebecca Huang, Daniel E Spratt, et al.
European Urology Oncology
|
July 17, 2025
Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 Trial
Ryan M Phillips, James A Proudfoot, Elai Davicioni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 4, 2023
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group
Ashish M Kamat, Andrea B Apolo, Marek Babjuk, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 19, 2018
Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer
Himanshu R Lukka, Stephanie L Pugh, Deborah W Bruner, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 3, 2023
Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial
Daniel E Spratt, Vinnie Y T Liu, Jeff Michalski, et al.
European Urology
|
June 26, 2025
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data
Sarah Burdett, David J Fisher, Jayne F Tierney, et al.
Page
of 28